- Home
- NRXS vs PLRX Comparison
NRXS vs PLRX Comparison
Compare NRXS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | PLRX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | 49 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9M | 81.7M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NRXS | PLRX |
|---|---|---|
| Price | $7.06 | $1.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.00 | $2.67 |
| AVG Volume (30 Days) | 208.8K | ★ 519.3K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.13 | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,569,282.00 | N/A |
| Revenue This Year | $142.91 | N/A |
| Revenue Next Year | $120.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $1.33 | $1.09 |
| 52 Week High | $7.97 | $1.95 |
Technical Indicators
Market Signals| Indicator | NRXS | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 56.09 |
| Support Level | $2.36 | $1.12 |
| Resistance Level | $7.97 | $1.39 |
| Average True Range (ATR) | 0.69 | 0.07 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 54.92 | 75.47 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.